4Eflhimiou P,Kontzias A,Ward CM,et al.Adult-onset Still's disease:can recent advances in our understanding of its pathogenesis lead to targeted therapy ?.Nat Clin Pract Rheumatol,2007,3(6):328-335.
6Eflhimiour P,Georgy S.Pathogenesis and management of adult onset Still's disease.Semin Arthritis Rheum,2006,36(3):144-152.
7Alekseeva EI,Shakhbazian IE.Criteria of aggressive rheumatoid arthritis course in children.Ter Arkh,1998,70(5):37-41.
8Nagasawa K.Central nervous system involvement in adult onset Still's disease.Intern Med,2003,42(10):930-931.
9Domingues RB,da Gama AM,Caser EB,et al.Disseminated cerebral thrombotic microangiopathy in a patient with adult'S still disease.Arq Neuropsiquiatr,2003,61(2A):259-261.
10Nishida T,Suzuki K,Kuwada N,et al.Hemophagocytic syndrome and adult Still's disease associated with meningoencephalitis and unconsciousness.Intern Med,2001,40(10):1037-1040.
2Efthimiou P, Kontzias A, Ward CM, et al. Aduh-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy? Nat Clin Pract Rheumatol, 2007, 3: 328-335.
3Kutukculer N, Caglayans S. Plasma and synovial fluid soluble CD23 concentrations in children with juvenile chronic arthritis. Autoimmunity, 1998, 27: 155-158.
4Zak M, Pedersen FK. Juvenile chronic arthritis into adulthood: a long-term follow-up study. Rheumatology (Oxford), 2000, 39: 198 -204.
5Chen DY, Lan JL, Lin FJ, et al. Predominance of Th1 cytokine in peripheral blood and pathological tissues of patients with active untreated adult onset Still's disease. Ann Rheum Dis, 2004, 63: 1300-1306.
6Fujii T, Nojima T, Yasuoka H, et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still's disease: association with chronic articular disease. Rheumatology (Oxford), 2001, 40: 1398-1404.
7Saikl O, Uda H, Nishimoto N, et al. Adult Still's disease reflects a Th2 rather than a Thl cytokine profile. Clin Immunol, 2004, 12: 120-125.
8Nakanishi K, Yoshimoto T, Tsutsui H, et al. Interleukin-18 is a unique cytokine that stimulates both Thl and Th2 responses depending on its cytokine milieu. Cytokine Growth Factor Rev, 2001, 12: 53-72.
9Yoshimoto T, Min B, Sugimoto T, et al. Nonredundant roles for CD1d-restricted natural killer T ceils and conventional CD4^+ T ceils in the induction of immunoglobulin E antibodies in response to interleukin 18 treatment of mice. J Exp Med, 2003, 197: 997-1005.
10McCarty MF. Reduction of serum C-reactive protein by statin therapy may reflect decreased isophenylation of Rac 1, a mediator of the IL-6 signal transduction pathway. Med Hypotheses, 2003, 60: 634-639.
